04.04.22 -- Listen Now: CAR T-cells for Ovarian Cancer, Cell and Gene Solid Tumor Therapies, and more.

Check out the latest episodes from Cell & Gene: The Podcast and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters including our podcast series. Don’t forget to subscribe so you never miss an episode!

BlueSphere Bio's CEO Dr. David Apelian explains the difficulties associated with treating solid tumor cancers as well as what the cell and gene (CGT) sector needs to get right in the short term and why.

Cue Biopharma's Anish Suri, Ph.D., explains why the clinical-stage biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body to transform the treatment of cancer.

Allan Shaw waxes on his expectations for M&A and collaborative partnership opportunities for new and emerging biotechs in 2022 and beyond. Learn what biotech leaders should be asking about intentionality, what's attractive to potential suitors, and why startups unprepared to go the distance have conceded a major factor in partnership/buyout negotiations. 

This episode of Business of Biotech is fire. It's an interview with SalioGen Therapeutics’ chairman and CEO, Ray Tabibiazar, M.D., whose last name literally translates to "Dr. Fire." Tune in to learn how he got that name, and how genomic coding — adding a new genomic code to turn on, off, or modify function of new or existing genes — works.

While success has been seen in animal models, solid tumors have proved a vexing challenge for CAR T-cell therapies. Here we're joined by Anixa Biosciences chairman, president, and CEO, Amit Kumar, Ph.D. Dr. Kumar shares on the company's progress with a CAR T-cell therapy that aims to attack both tumor cells and the tumor vasculature, in hopes that it might be the first to destroy solid ovarian cancers.

With its hypothesis-free, target-free, AI-driven drug discovery platform, Fountain Therapeutics is turning the traditional drug discovery pathway on its ear to address a variety of age-related disease. Fountain CEO, William Greene, M.D., joins us to discuss the approach, its rationale, and how the company is applying substantial support from the likes of Eli Lilly, Alexandria Venture Investments, R42 Group, Khosla Ventures, and Nan Fung Life Sciences.